In our previous research we developed highly conformal radiation treatment for head/neck and brain tumors using sculpted dose distributions and demonstrated the ability to escalate tumor dose with minimal complications (brain), and maintain high control rates while decreasing a major complication (xerostomia) for head/neck cancers. Our long-term goal is to increase tumor control and reduce complication rates by individualizing the timing and intensity of therapy based on innovative imaging. We propose to intensify treatment for glioblastoma by escalating the daily fraction doses while also utilizing effective chemotherapy (temozolomide). We will test the hypothesis that diffusion MRI (dMRI), which may predict tumor response early after therapy is started, will be a useful basis for re-optimization during the course of treatment, allowing the escalation of dose to non-responding parts of the tumor. We will also make use of our preliminary MRI results which suggest that radiation can open the bloodtumor- barrier (BTB) to chemotherapeutic and radiosensitizing agents (like gemitabine). We will test whether concurrent conformal radiation and gemcitabine (administered after the BTB is opened) will be safer and improve response rates for grade 3 gliomas, and whether we can improve the outcome by escalating the doses to the parts of the tumor demonstrating lack of increased permeability of the BTB early after the start of therapy. In head and neck cancer, we will test strategies that promise to decrease treatment-related late dysphagia and aspiration. We will test if reducing dose to the swallowing structures can reduce the severity of late dysphagia, and test the utility of innovative imaging (FLT-PET, and dMRI) to predict (early after the start of therapy) which tumors are likely to fail treatment, as well as directing individualized dose intensification using re-optimization plans. We expect that the Project will show improving non-complicated tumor control rates in brain and head and neck cancer by customizing treatment intensity following analysis of possible early predictors of response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059827-15
Application #
8102828
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
15
Fiscal Year
2010
Total Cost
$345,259
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Ohri, Nitin; Tomé, Wolfgang A; Méndez Romero, Alejandra et al. (2018) Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys :
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Wang, Shulian; Campbell, Jeff; Stenmark, Matthew H et al. (2018) A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiother Oncol 126:506-510
Sapir, Eli; Tao, Yebin; Schipper, Matthew J et al. (2018) Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:122-130
Hawkins, Peter G; Boonstra, Philip S; Hobson, Stephen T et al. (2018) Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Transl Oncol 11:102-108
Sun, Yilun; Hawkins, Peter G; Bi, Nan et al. (2018) Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 100:107-114
Kong, Feng-Ming Spring; Li, Ling; Wang, Weili et al. (2018) Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol :
Shilkrut, Mark; Sapir, Eli; Hanasoge, Sheela et al. (2018) Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 41:326-331
Jackson, William C; Tao, Yebin; Mendiratta-Lala, Mishal et al. (2018) Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys 100:950-958
Miften, Moyed; Vinogradskiy, Yevgeniy; Moiseenko, Vitali et al. (2018) Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 289 publications